FAIM
INMB icon

Financial Advocates Investment Management’s INmune Bio INMB Stock Holding History

Financial Advocates Investment Management’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-11,510
Closed -$78.3K – 759
2023
Q3 		$78.3K Hold
11,510
– – 0.01% 684
2023
Q2 		$106K Buy
+11,510
New +$92.4K 0.01% 671

Other funds holding INMB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Financial Advocates Investment Management's INMB Position: Q3 2025 in Review

Financial Advocates Investment Management sold out of INmune Bio (INMB) in Q3 2025, closing a stake of 15,500 shares — an estimated $35.8K sold.

Financial Advocates Investment Management first reported a position in INMB in Q3 2019 and held it in 21 quarters. The position peaked at $1.33M in Q3 2019. 73 funds tracked by Wall St. Rank hold INMB as of Q3 2025.

  • Financial Advocates Investment Management reported no remaining INmune Bio position as of Q3 2025 after selling out during the quarter.
  • Financial Advocates Investment Management sold 15,500 INmune Bio shares in Q3 2025, an estimated $35.8K.
  • Financial Advocates Investment Management first reported a position in INmune Bio in Q3 2019 and held it in 21 quarters.
  • Financial Advocates Investment Management's INmune Bio position peaked at $1.33M in Q3 2019.
  • 73 funds tracked by Wall St. Rank held INmune Bio as of Q3 2025.

Based on Financial Advocates Investment Management's 13F filing for Q3 2025, filed 6 Nov 2025.